In the present study, we evaluate the prevalence of KDD in ERBB family members (EGFR/EGFR, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) across multiple types of human cancers in order to refine our understanding of KDD as an oncogenic driver. This evidence concerns the gene ERBB2 and cancer.